Peptide Half-Life Explained: Why Some Last Minutes, Others Days
By PeptideChat Team · September 24, 2026
Two peptides can act on the same receptor and still behave completely differently in the body. One is gone within minutes; another is still circulating a week later. The difference is almost always half-life, and it is usually the result of deliberate chemistry. This guide explains what half-life means, why natural peptides disappear so quickly, and the engineering tricks that keep modern peptide drugs around, using only figures from published studies.
What half-life means
Half-life is the time it takes for the concentration of a drug in the blood to fall by half. After one half-life, 50% remains; after two, 25%; after three, 12.5%, and so on. It is one part of pharmacokinetics, the study of how the body absorbs, distributes and clears a substance.
Half-life also sets how long a drug takes to build up with repeated doses. Semaglutide, for example, has a half-life of about 7 days, so with weekly dosing it reaches steady state (a stable level from dose to dose) in 4–5 weeks (Hall 2018).
One caution: plasma half-life is not the same as duration of effect. When GHRH(1-29), the active fragment of growth-hormone-releasing hormone, was injected intravenously into healthy men, it was rapidly eliminated, yet growth hormone levels stayed elevated for about 3 hours (Wilton 1993). A short-lived signal can set off a longer downstream response.
Why native peptides are cleared in minutes
Natural peptide hormones are built to be brief. The body uses them as signals, and signals need to switch off. Two processes do most of the clearing (Werle 2006):
- Enzymatic breakdown (proteolysis). Enzymes in the blood, liver and kidney cut peptide bonds, each at its own preferred sites.
- Renal clearance. Small molecules are filtered out of the blood by the kidneys.
A 2018 review put the typical in-vivo half-life of therapeutic peptides and proteins at just a few minutes to hours (Tan 2018). Some concrete measurements:
- GLP-1. When native GLP-1 was infused into healthy people, intact hormone made up only about 20% of the measured peptide; the rest had already been clipped at one end into a shorter fragment (Deacon 1995).
- GHRH(1-29). During intravenous infusion in healthy men, its disappearance half-time was 4.3 minutes (Soule 1994).
- BPC-157. In rats and dogs, the elimination half-life of intact BPC-157 was under 30 minutes, and it was rapidly broken down into small fragments and single amino acids (He 2022).
The engineering tricks that extend half-life
Drug developers attack both clearance routes. Reviews group the most widely used strategies into two families: slowing renal clearance, and piggybacking on the body's own long-lived proteins such as albumin (Tan 2018).
1. Amino-acid substitutions
Swapping one building block for an unusual one can make a cutting site unrecognizable to enzymes. Replacing the second amino acid of GHRH(1-29) with D-alanine (a mirror-image form) lengthened its disappearance half-time from 4.3 to 6.7 minutes and roughly halved its metabolic clearance rate (Soule 1994). The effect can be much larger: by shortening somatostatin and substituting D-amino acids, developers produced octreotide, with a plasma half-life of 1.5 hours versus only a few minutes for the original hormone (Werle 2006).
2. Fatty-acid acylation and albumin binding
Albumin is a major blood protein that the body recycles rather than quickly clearing (Tan 2018). Attach a fatty acid to a peptide and it will cling to albumin, which shields it from enzymes and keeps it out of the kidney filter.
- Liraglutide carries a 16-carbon fatty acid chain that binds albumin noncovalently. This slows absorption from the injection site and protects the molecule from the enzyme DPP-4, giving an elimination half-life of 13 hours, enough for once-daily dosing (Sisson 2011).
- Semaglutide was designed to push the same idea further. Its developers increased its albumin affinity and made two amino-acid substitutions (Aib8 and Arg34) as part of a design aimed at full stability against metabolic breakdown. In mini-pigs, its intravenous plasma half-life was 46.1 hours (Lau 2015); in people it is about 7 days (Hall 2018).
See the semaglutide and liraglutide pages for their clinical research.
3. DAC: a covalent hook for albumin
DAC (Drug Affinity Complex) takes a different route to the same destination. Instead of a fatty acid, the peptide carries a reactive chemical group that forms a covalent bond with a specific site (cysteine 34) on circulating albumin. Researchers built several albumin-reactive versions of GHRH(1-29); the best, CJC-1295, was still present in rat plasma beyond 72 hours and was found attached to albumin (Jetté 2005).
In healthy adults, the estimated half-life of CJC-1295 was 5.8–8.1 days (Teichman 2006). Compare that with the 4.3 minutes measured for unmodified GHRH(1-29) above: the same active sequence, stretched from minutes to days.
An important practical note: that multi-day figure belongs to the DAC version. Products sold as "CJC-1295 no DAC" lack the albumin-binding group, so the Teichman half-life does not apply to them. The CJC-1295 vs Sermorelin comparison covers how the long-acting and short-acting GHRH analogs differ.
4. PEGylation
PEGylation attaches chains of polyethylene glycol (PEG), a water-loving polymer, to a peptide or protein. The bulkier molecule is filtered by the kidneys more slowly and is partly shielded from enzymes. One PEGylated form of interferon alpha-2b had a plasma half-life 330-fold longer than the native protein (Werle 2006). In a human study, a PEG-conjugated GHRH raised growth hormone for 12 hours after a single dose in young men; injection-site reactions were more frequent than with placebo, though mild and transient (Munafo 2005).
Side-by-side
| Compound | Modification | Reported half-life | Where measured |
|---|---|---|---|
| GHRH(1-29) | None | 4.3 min | Healthy men, IV infusion (Soule 1994) |
| D-Ala2-GHRH(1-29) | One amino-acid swap | 6.7 min | Healthy men, IV infusion (Soule 1994) |
| BPC-157 | None | Under 30 min | Rats and dogs (He 2022) |
| Liraglutide | Fatty acid, albumin binding | 13 h | Review of clinical data (Sisson 2011) |
| CJC-1295 (with DAC) | Covalent albumin binding | 5.8–8.1 days | Healthy adults (Teichman 2006) |
| Semaglutide | Fatty acid plus two amino-acid swaps | About 7 days | Review of clinical data (Hall 2018) |
Numbers from different species, routes and methods are not directly interchangeable. The table shows orders of magnitude, not precise comparisons.
Why half-life matters to you as a reader
Half-life explains why some compounds are studied with weekly injections and others with several doses a day. It also cuts the other way. A long half-life means a drug takes longer to leave the body if side effects appear, and repeated doses can accumulate: with multiple CJC-1295 doses, IGF-1 stayed above baseline for up to 28 days (Teichman 2006).
When you see a half-life quoted for a peptide, check three things: which molecule it was measured for (with or without a modification), in which species, and by which route. A figure for one version does not carry over to another.
Sources
- Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. Clin Pharmacokinet, 2018. PMID 29915923
- Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl, 1993. PMID 8329825
- Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids, 2006. PMID 16622600
- Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins. Curr Pharm Des, 2018. PMID 30727869
- Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995. PMID 7657039
- Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab, 1994. PMID 7962295
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol, 2022. PMID 36588717
- Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy, 2011. PMID 21923591
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem, 2015. PMID 26308095
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006. PMID 16352683
- Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. Eur J Endocrinol, 2005. PMID 16061831
This article is for educational and research purposes only and is not medical advice.